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Abstract
Background: Mesenchymal stem cells have properties that make them amenable to therapeutic use. However, the
acceptance of mesenchymal stem cells in clinical practice requires standardized techniques for their specific
isolation. To date, there are no conclusive marker (s) for the exclusive isolation of mesenchymal stem cells. Our aim
was to identify markers differentially expressed between mesenchymal stem cell and non-stem cell mesenchymal
cell cultures. We compared and contrasted the phenotype of tissue cultures in which mesenchymal stem cells are
rich and rare. By initially assessing mesenchymal stem cell differentiation, we established that bone marrow and
breast adipose cultures are rich in mesenchymal stem cells while, in our hands, foreskin fibroblast and olfactory
tissue cultures contain rare mesenchymal stem cells. In particular, olfactory tissue cells represent non-stem cell
mesenchymal cells. Subsequently, the phenotype of the tissue cultures were thoroughly assessed using
immuno-fluorescence, flow-cytometry, proteomics, antibody arrays and qPCR.
Results: Our analysis revealed that all tissue cultures, regardless of differentiation potential, demonstrated
remarkably similar phenotypes. Importantly, it was also observed that common mesenchymal stem cell markers,
and fibroblast-associated markers, do not discriminate between mesenchymal stem cell and non-stem cell
mesenchymal cell cultures. Examination and comparison of the phenotypes of mesenchymal stem cell and
non-stem cell mesenchymal cell cultures revealed three differentially expressed markers – CD24, CD108
and CD40.
Conclusion: We indicate the importance of establishing differential marker expression between mesenchymal
stem cells and non-stem cell mesenchymal cells in order to determine stem cell specific markers.
Keywords: Mesenchymal stem cell, Cell surface markers, Bone marrow mesenchymal stem cell, Breast adipose
stem cell, Fibroblasts and olfactory
Background
Mesenchymal stem cells are plastic-adherent, fibroblast-
like cells that differentiate into mesodermal cells - osteo-
cytes, adipocytes and chondrocytes [1]. Although first
isolated from bone marrow, mesenchymal stem cells have
been identified in numerous tissues including, but not lim-
ited to; adipose tissue, skeletal muscle, dental pulp, dermal
tissue [2-6]. Numerous clinical trials have been completed
or are currently underway utilizing the advantageous
properties of mesenchymal stem cells to treat an array of
disorders [7-9]. It seems apparent that these remarkable
cells have significant therapeutic potential. Although, to be
accepted in routine clinical practice, standardized tech-
niques for the exclusive isolation of mesenchymal stem
cells are required. Consequently, the identification of spe-
cific extracellular markers is crucial.
However, to date, there are no conclusive extracellular
marker (s) for the specific isolation of mesenchymal stem
cells. Since the initial work of Haynesworth et al (1992)
[10], an abundance of markers / marker combinations have
been suggested to enrich for mesenchymal stem cells,
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examine the phenotype of mesenchymal stem cells, assess
o n l yo n et i s s u et y p eo rc o m p a r em e s e n c h y m a ls t e mc e l l s
from various tissues [12,13]. The majority do not contrast
the phenotype of mesenchymal stem cells with non-stem
cell mesenchymal cells. Therefore, the aim of this project
was to identify markers differentially expressed between
mesenchymal stem cell and non-stem cell mesenchymal
cell cultures by comparing and contrasting the phenotype
of populations of cells from tissues in which mesenchymal
stem cells are rich and rare. We took an inclusive approach
to this exploratory work to avoid inadvertent exclusion of
mesenchymal stem cells. Hence, no selection or sorting
techniques were applied to our tissue cultures, save for
those prescribed by Dominici et al 2006 [14]; plastic adher-
ence and proliferation in standard tissue culture conditions.
Cells from bone marrow, olfactory tissue, foreskin fi-
broblasts and breast adipose were assessed for tri-
lineage differentiation potential (adipocytes, osteocytes
and chondrocytes) and their phenotype extensively eval-
uated utilizing flow-cytometry, immuno-fluorescence,
proteomics, antibody arrays and qPCR. Differentiation
experiments revealed cultures in which mesenchymal
stem cells are rich and rare (non-stem cell mesenchymal
cell cultures). Phenotypic analysis demonstrated that all
tissue cultures exhibited remarkably similar phenotypes
and that common mesenchymal stem cell markers, and
fibroblast-associated markers, do not discriminate between
mesenchymal stem cell and non-stem cell mesenchymal
cell cultures. Meticulous examination and comparison of
the phenotypes of mesenchymal stem cell and non-stem
cell mesenchymal cell cultures revealed few differentially
expressed markers.
Results
Bone marrow and breast adipose cultures are rich in
mesenchymal stem cells, while olfactory tissue cultures
represent non-stem cell mesenchymal cells
One of the hallmarks of mesenchymal stem cells is their
tri-lineage differentiation potential (adipocytes, chondro-
cytes and osteocytes). To assess the differentiation of tis-
sue cells, standard differentiation techniques were applied.
Bone marrow and breast adipose cells demonstrated ex-
tensive adipocyte, osteocyte and chondrocyte differenti-
ation (Figure 1B,H,C,I;A,G). Foreskin fibroblasts exhibited
chondrocyte and rare adipocyte and osteocyte differenti-
ation (Figure 1J-L). However, olfactory tissue cells dis-
played no chondrocyte and very rare adipocyte and
osteocyte differentiation (Figure 1D-F). qPCR for aggre-
can (chondrocytes), adiponectin (adipocytes) and osteo-
pontin (osteocytes) confirmed cytochemical staining
results (Figure 1M). These data indicate that bone mar-
row and breast adipose cells demonstrated differenti-
ation properties consistent with populations rich in
mesenchymal stem cells. The differentiation potential of
foreskin fibroblasts and olfactory tissue cells indicated
populations in which mesenchymal stem cells are rare.
In particular, olfactory tissue cells represent non-stem
cell mesenchymal cells (Table 1).
Differential phenotypic analysis
Having established the differentiation potential of the vari-
ous tissue cultures, attempts were made to identify markers
differentially expressed between mesenchymal stem cell
(bone marrow and breast adipose) and non-stem cell mes-
enchymal cell (olfactory tissue) cultures. To achieve this
flow-cytometry, immuno-fluorescence, proteomics, anti-
body arrays and qPCR were employed.
Common mesenchymal stem cell markers do not
discriminate between mesenchymal stem cell and non-
stem cell mesenchymal cell cultures
Flow-cytometry was used to assess the tissue cells for
the expression of markers associated with mesenchymal
stem cells, as well as other extracellular markers. Flow-
cytometry data indicated that common mesenchymal
stem cell markers CD13, CD29, CD44, CD73, CD90 and
CD105 were expressed by very high percentages of cells
across all four tissue groups (Figure 2A). Amongst the 17
markers tested, four demonstrated significant differences
in the percentage of positive cells (P< 0.05); CD10, CD49a,
CD166 and Stro-1 (Figure 2A). None demonstrated signifi-
cant differential expression between mesenchymal stem
cell (bone marrow and breast adipose) and non-stem cell
mesenchymal cell (olfactory tissue) cultures. Additionally,
all tissue cells tested were negative for endothelial marker
CD31 and hematopoietic markers (CD34, CD45 and
CD11b) – data not shown.
Fibroblast-associated markers do not discriminate
between mesenchymal stem cell and non-stem cell
mesenchymal cell cultures
As markers associated with mesenchymal stem cells
largely could not distinguish between mesenchymal stem
cell and non-stem cell mesenchymal cell cultures, it was
hypothesized that fibroblast-associated markers may prove
more discriminatory.
Immuno-fluorescence studies revealed that most cells
amongst the various tissue cultures expressed fibroblast-
associated markers; Collagens I and III, FSP and P4HB
(Figure 2B-F). No significant difference was observed be-
tween all tissue cells in regard to the expression of these
markers (P >0.05).
All tissue cultures displayed a remarkably
similar phenotype
Flow-cytometry and immuno-fluorescence experiments
were ineffective in distinguishing between cultures in
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ing the phenotypic similarity of the tissue cultures. Anti-
body array and proteomic experiments further emphasized
this phenotypic similarity. Proteomic analysis of whole cell
lysates (Figure 3A-D) and pair-wise analysis of quantitative
expression levels of protein spots from all tissue cells re-
vealed correlation coefficients equal to or greater than 0.8
for all tissue pairs (Figure 3E). No significant difference in
the correlation coefficients was found between the four
tissue groups (P> 0.05).
Likewise, antibody array experiments established that
cells from all tissues demonstrated congruent expression
of 197 (46 all positive and 151 all negative across the four
tissue types) out of 228 (86.4%) antibodies tested. Pair-
Figure 1 Tri-lineage differentiation potential of tissue cells. Cells from bone marrow (BM) (A-C), breast adipose (BA) (D-F), foreskin fibroblasts
(FF) (G-I) and olfactory tissue (OT) (J-L), and were exposed to conditions known to induce the differentiation of mesenchymal stem cells into
chondrocytes, adipocytes and osteocytes. Cytochemical stains were carried out to indicate differentiation; Safranin O (chondrocytes: A, D, G,
J-Scale bar (J)=200 μm), Oil-red-O (adipocytes: B, E, H, K whole well scans (5×5 montage) Scale bar (K)= 1 mm: inset-Scale bar (K)=40μm) and
Alizarin Red (osteocytes: C, F-Scale bar (F)=100 μm: I, L-Scale bar (L)=5 0μm). All images are representative except for F and L which portray very
rare osteocyte staining in FF and OT cultures. M: Illustrates confirmation and quantitation of differentiation by qPCR. Taqman probes for aggrecan,
adiponectin and osteopontin were used to quantitate chondrocyte, adipocyte and osteocyte differentiation respectively amongst our tissue
samples. ΔΔCt values were calculated relative to GAPDH and were normalized relative to BM (N= 3/cell type). Standard error is displayed and
significant differences between tissue types (P<0.05) are indicated (*). RNA was extracted on the same day as cytochemical analysis;
chondrocytes (day 21), adipocytes (day 25) and osteocytes (day 21).
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were considered as either positive (+) or negative (−)
(Figure 3F and G), revealed greater than 90% similarity
between all tissue pairs (Figure 3H).
Identification of markers differentially expressed between
mesenchymal stem cell and non-stem cell mesenchymal
cell cultures
Meticulous examination and comparison of the prote-
omic and antibody array profiles of mesenchymal stem
cell (breast adipose and bone marrow) and non-stem cell
mesenchymal cell (olfactory tissue) cultures revealed
differentially expressed markers. Analysis of proteomic
data revealed six intracellular proteins expressed more
highly in tissue cultures rich in mesenchymal stem cells;
actin - cytoplasmic 1 and 2, alpha internexin, alpha eno-
lase, endoplasmin and neurofilament light polypeptide
(Figure 4 and Additional file 1). Similarly, investigation
of antibody array data uncovered nine extracellular
markers; CD24, CD26, CD49d, CD51/61, CD87, CD108,
CD141, CD200 and SSEA-1 expressed in tissue cultures
rich in mesenchymal stem cells and absent in olfactory
tissue cultures (Figure 4A). Of these markers only CD24,
CD26, CD87, CD108, neurofilament light polypeptide
and endoplasmin demonstrated qPCR expression pro-
files consistent with antibody array or proteomic analysis
(Figure 4B). Significantly increased expression (P>0.05)
between cultures rich in mesenchymal stem cells and
non-stem cell mesenchymal cells was only detected in
CD24 and CD108 (Figure 4B).
Analysis of proteins expressed more highly in non-
stem cell mesenchymal cell cultures (olfactory tissue
cells) than tissue cultures rich in mesenchymal stem
cells (breast adipose and bone marrow) presented six
intracellular proteins; annexin II, desmin, tropomyosin
alpha 1,3 and 4 chain and vimentin. Antibody array data
disclosed five potential markers, expressed only by
Table 1 Summary of differentiation data
Differentiation
Adipocyte Osteocyte Chondrocyte
Bone marrow ++ ++ ++
Breast adipose ++ ++ ++
Olfactory tissue +/− +/− -
Foreskin fibroblasts +/− +/− ++
Bone marrow, breast adipose, olfactory tissue and foreskin fibroblast cells were
tested for their ability to function as mesenchymal stem cells by examining
their tri-lineage (adipocyte, osteocyte and chondrocyte) differentiation
potential. Extensive (++), moderate (+), rare (+/−) and negative (−)
differentiation is indicated.
Figure 2 Phenotypic analysis of tissue cells by flow-cytometry and immuno-fluorescence. A: Bone marrow (BM), breast adipose (BA),
olfactory tissue (OT) and foreskin fibroblast (FF) cells were analyzed by flow-cytometry for the expression of 17 extracellular markers and the percentage
of positive cells calculated compared with unstained controls (N=3/cell type). Standard error is presented and significant differences between tissue
types (P<0.05) are indicated (*). B: Tissue cells were analyzed for the expression of fibroblast-associated markers; fibroblast surface protein (FSP)
(C -olfactory tissue cells), Collagen 3 (Coll 3) (D – bone marrow cells ) prolyl-4-hydroxylase, beta polypeptide (P4HB) (E – breast adipose cells), and
Collagen 1 (Coll 1) (F – foreskin fibroblast cells) using immuno-fluorescence. Scale bar (F)=50μm - applicable to C, D and E. The percentage of positive
cells was calculated compared with no primary antibody controls (N=3/cell type). Standard error is demonstrated - no significant differences between
tissue types were found.
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ligand and CD171 (Figure 4A). Of these markers only
CD40 illustrated a qPCR expression profile with signifi-
cantly increased expression (P>0.05) between non-
stem cell mesenchymal cell cultures and cultures rich in
mesenchymal stem cells (Figure 4A).
Discussion
The aim of this project was to identify markers differen-
tially expressed between mesenchymal stem cell and non-
stem cell mesenchymal cell cultures. This was achieved by
comparing and contrasting the phenotype of populations
of cells from tissues in which mesenchymal stem cells are
Figure 3 Proteomic and antibody array analysis of tissue cells. A-E: Proteomic analysis of 2-DE gels, visualized with Sypro ruby, derived from
bone marrow (BM) (A), breast adipose (BA) (B), olfactory tissue (OT) (C) and foreskin fibroblast (FF) (D) cells. E: Table indicating correlation analysis
of protein expression profiles of 2-DE gels derived from BM, BA, OT and FF cell samples (N= 2 samples per tissue). Quantitative expression levels
of matched protein spots on 2-DE gels were compared pair-wise. Note; multiple runs of the same sample generated a correlation coefficient of
0.88 (N=3). F-H: Antibody array analysis of BM, BA, OT and FF cells. Three samples per tissue were pooled and stained for extracellular antibodies
(228) using the BD lyoplate kit and images captured (3x3 montage). Representative images of positive (F:B M– CD105) and negative (G:O T– CD200)
wells – Scale bar (G)=10 0μm. H: A pair-wise comparison of positive or negative antibody expression was carried out between all tissue cells and the
percentage similarity between samples calculated.
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potential of tissue cultures, we demonstrated that bone
marrow and breast adipose cultures are rich in mesenchy-
mal stem cells while, in our hands, foreskin fibroblasts and
olfactory tissue cultures contain rare mesenchymal stem
cells. In particular, olfactory tissue cells represent non-
stem cell mesenchymal cells. Phenotypic analysis revealed
that all tissue cultures, irrespective of differentiation po-
tential, exhibited remarkably similar phenotypes. Import-
antly, it was also revealed that common mesenchymal
stem cell markers, and fibroblast-associated markers, do
not discriminate between mesenchymal stem cell and
non-stem cell mesenchymal cell cultures. Examination
and comparison of the phenotypes of mesenchymal stem
cell and non-stem cell mesenchymal cell cultures revealed
few differentially expressed markers.
Despite a plethora of markers/marker combinations be-
ing proposed to enrich for mesenchymal stem cells
(reviewed in [11]), to date, there is no conclusive extracellu-
l a rm a r k e r( s )f o rt h es p e c i f ic isolation of mesenchymal
stem cells. Our data also suggests that some reported mes-
enchymal stem cell markers may not discriminate between
mesenchymal stem cell and non-stem cell mesenchymal
cells. To ensure the inclusion of mesenchymal stem
cells in this exploratory work no selection or sorting
techniques were applied to our tissue cultures. Subse-
quently, it is inevitable that there is a degree of hetero-
geneity amongst our tissue cultures. The ‘all-or-nothing’
differentiation (Figure 1) and immuno-staining patterns
(Figure 2) exhibited in our tissue cultures however,
w o u l ds u g g e s tad e g r e eo fh o m o g e n e i t y .
Ideally, homogeneous, clonal, mesenchymal stem cell
and non-stem cell mesenchymal cell cultures would be
compared to identify differentially expressed markers.
However, as there are no conclusive, specific, extracel-
lular markers for mesenchymal stem cells it would be
difficult to ensure that clonal cell lines are ‘true’ mes-
enchymal stem cells. Also the additional expansion
required from clonal cells to achieve sufficient cell
numbers for all our experiments would increase the
emergence of spontaneous phenotypic heterogeneity,
even amongst clonal populations [15,16]. Therefore,
unselected cultures were utilized in this exploratory
study.
Figure 4 Identification of markers differentially expressed between cultures rich in mesenchymal stem cells and non-stem cell
mesenchymal cell cultures. A: Analysis of antibody array and proteomics data identified markers upregulated in cultures rich in mesenchymal
stem cells (bone marrow – BM; and breast adipose - BA), compared with non-stem cell mesenchymal cell cultures (olfactory tissue – OT).
Antibody array and proteomics data also identified markers upregulated in non-stem cell mesenchymal cultures (OT) compared with cultures rich
in mesenchymal stem cell (BM and BA). B: qPCR was carried out on all tissues (N=3/cell type) for markers identified in A. Only markers found to
have expression profiles consistent with A are represented (NFL: neurofilament light polypeptide; END: endoplasmin). ΔΔCt values were
calculated relative to GAPDH and were normalized relative to the tissue with the highest expression. Standard error is displayed - only significant
differences between tissue types, consistent with A, (P<0.05) are indicated (*).
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Both bone marrow and breast adipose cultures demon-
strated the tri-lineage differentiation potential expected of
populations rich in mesenchymal stem cells; extensive dif-
ferentiation into adipocytes, chondrocytes and osteocytes
[1]. However, foreskin fibroblast cultures only indicated a
potential to differentiate into chondrocytes. The vast major-
ity of foreskin fibroblast cells did not differentiate into adi-
pocytes and osteocytes. As yet, there is little consensus on
the tri-lineage potential of foreskin fibroblasts [12,17-19].
T h ed a t ap r e s e n t e dh e r ei sc o n s i s t e n tw i t ho t h e rr e p o r t s
that suggest that foreskin fibroblast cultures may contain
cells with tri-lineage differentiation potential, but in our
hands this population appears to be rare [12,17-19]. There-
fore, we considered these cultures to contain rare mesen-
chymal stem cells and that the predominant population are
non-stem cell mesenchymal cells.
Olfactory tissue cultures ostensibly failed to differenti-
ate into adipocytes, osteocytes and chondrocytes. Few
studies have examined olfactory tissue for the presence
of mesenchymal stem cells. Direct comparison of these
studies is made more difficult by discrepancies in both
the source of nasal cells as well as culture techniques
[20-23]. To date, convincing, extensive tri-lineage poten-
tial of olfactory cells has not been demonstrated. How-
ever, recent reports suggest that olfactory cells are able
to differentiate into osteocytes, rarely differentiate into
adipocytes and may or may not differentiate into chon-
drocytes [20-23]. Overall, our data suggests that if olfac-
tory tissue cultures contain tri-potent mesenchymal
stem cells they are very rare and that, in our hands, they
represent non-stem cell mesenchymal cells.
Phenotypic analysis
Attempts were made to distinguish between mesenchymal
stem cell and non-stem cell mesenchymal cell cultures by
examining common mesenchymal stem cell markers and
fibroblast-associated markers. The majority of reports
evaluating the immuno-phenotype of different tissue
sources of mesenchymal stem cells accentuate their
similarity. In particular the high expression of mesen-
chymal stem cell associated markers such as CD90,
CD73, CD29, CD44, CD105 and CD13 are often empha-
sized [13,19,21-23]. Here we clearly show that non-stem
cell mesenchymal cells from olfactory tissue and fore-
skin fibroblasts demonstrate the same expression of
these markers as mesenchymal stem cells derived from
bone marrow and breast adipose. Hence, the expression
of these markers may be indicative of mesenchymal cells,
in general, but are not specific to mesenchymal stem cells.
Likewise, the expression of fibroblast-associated markers
did not discriminate between mesenchymal stem cell cul-
tures and non-stem cell mesenchymal cell cultures.
While flow-cytometry and immuno-fluorescence experi-
ments did not distinguish between cultures in which mes-
enchymal stem cells are rich and rare, they did indicate the
phenotypic similarity of the different tissue cultures. Prote-
omic (correlation coefficients) and antibody array (percent-
age similarity) data further emphasized the remarkable
phenotypic similarity of the tissue cultures, regardless of
their ability to differentiate as mesenchymal stem cells.
Proteomics allowed the comparison of ~550 protein
spots per sample and identified, actin - cytoplasmic 1 and
2, alpha internexin, alpha enolase, endoplasmin and neu-
rofilament light polypeptide as being upregulated in mes-
enchymal stem cell cultures. While cytoplasmic actin 1
and 2 are ubiquitous, alpha internexin and neurofilament
light polypeptide are both associated with neural cells.
Interestingly, other studies have revealed that mesenchy-
mal stem cells express neurofilament light polypeptide as
well as other neural markers [24,25]. However, none of
these proteins were validated as differentially expressed
between mesenchymal stem cell and non-stem cell mesen-
chymal cell cultures by qPCR.
Antibody arrays afforded an examination of 228 extra-
cellular antibodies. Amongst these markers, only three
were validated by qPCR to be significantly differentially
expressed between mesenchymal stem cell and non-
stem cell mesenchymal cell cultures. CD108 and CD24
were found to have significantly increased expression be-
tween mesenchymal stem cell and non-stem cell mesen-
chymal cell cultures. CD108 is reportedly expressed by a
variety of cell types [26-28]. However, the association of
CD108 with immune regulation [26,29], angiogenesis
[30] and bone cell differentiation [27] is consistent with
the function of mesenchymal stem cells. CD24 is also
expressed by a range of cell types (reviewed by [31]), but
it is commonly affiliated with cancer stem cells [32,33].
Renal [34] and neural [35] stem cells also express CD24.
More importantly, Sonoyama et al 2006 [36] suggested
CD24 as a specific marker for a population of mesenchy-
mal stem cells in the human tooth.
Only CD40 was identified as significantly increased in
non-stem cell mesenchymal cultures compared with cul-
tures rich in mesenchymal stem cells. CD40 is expressed
by a variety of immune and non-immune cells. Consistent
with our findings, numerous reports have identified CD40
expression amongst fibroblasts from a wide variety of tis-
sues [37-39].
Conclusion
Mesenchymal stem cells have unique properties that make
them amenable to a variety of clinical applications. In order
to be accepted as routine clinical devices standardized
techniques for their exclusive isolation need to be devel-
oped. The identification of extracellular markers specific to
mesenchymal stem cells is crucial for their isolation. By
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enchymal stem cell and non-stem mesenchymal cell cul-
tures we demonstrate the importance of comparing and
contrasting mesenchymal cell types in order to determine
stem cell specific markers. Using this approach we revealed
that commonly reported mesenchymal stem cell markers
do not discriminate between mesenchymal stem cells and
non-stem cell mesenchymal cells. However, by thoroughly
analyzing and comparing the phenotypes of mesenchymal
stem cell and non-stem cell mesenchymal cell cultures we
identified only three differentially expressed markers –
CD24, CD108 and CD40. To our knowledge, this study is
the first to thoroughly analyze differential expression be-
tween human mesenchymal stem cell and non-stem cell
mesenchymal cell cultures incorporating flow-cytometry,
immuno-fluorescence, proteomics, antibody arrays and
qPCR.
Methods
Patients
Human olfactory tissue (n=3) and breast tissue (n=3)
were collected with informed consent with the approval of
the King Faisal Specialist Hospital and Research Centre
(KFSH & RC) Office of Research Affairs (RAC # 2080
007). Anonymised neonatal foreskins (n=3) and bone
marrow (n=3) samples were collected as waste tissues
with the approval of the KFSH & RC Office of Research
Affairs. Samples were neither age nor sex matched.
Olfactory tissue cultures
Olfactory biopsies were collected from the superior and
middle turbinates and posterior septum. Biopsies were
combined in tissue culture media; DMEM/HAM F-12
media (Invitrogen) supplemented with 10% fetal calf serum
(Lonza) and 1% penicillin streptomycin (Sigma-Aldrich).
Biopsies were finely minced then digested in 1 mL of Colla-
genase type XI (500units/mL) (Sigma-Aldrich) for 15 mi-
nutes at 37°C with trituration every 3 minutes. Collagenase
was diluted with the addition of 9 mL of tissue culture
media and the cells centrifuged (300 g, 5 minutes) prior to
plating at 37°C, 5%CO2 in tissue culture media.
Bone marrow cultures
Bone marrow aspirates were collected from patients
undergoing bone marrow transplantation. After CD34+
cells were harvested for clinical use, the remaining
CD34
- cells, designated to be discarded, were collected
in Phosphate Buffered Saline (PBS) (Sigma-Aldrich),
centrifuged (300 g, 5 minutes) and resuspended in tissue
culture media; DMEM/HAM F-12 media (Invitrogen)
supplemented with 10% fetal calf serum (Lonza) and 1%
penicillin streptomycin (Sigma-Aldrich) and plated at
37°C, 5%CO2.
Breast adipose cultures
Normal breast tissue samples were collected and processed
as described in Ghebeh et al 2007 [40]. Briefly, tissues were
minced and digested overnight with Collagenase Ia
(400 IU) and Hyaluronidase (100 IU) (Sigma-Aldrich) in
tissue culture media. After differential centrifugation (90 g,
2 minutes), floating adipose tissue was collected, diluted in
tissue culture media (1:10) and vortexed briefly. Adipose
cells were then pelleted by centrifugation (400 g, 5 minutes)
and set aside. Remaining floating adipose tissue - contain-
ing adipose cells - was processed again in the same way;
collected, diluted in tissue culture media, vortexed and cen-
trifuged (400 g, 5 minutes). This process was repeated a fur-
ther two times. Subsequently, all cells were pooled together
(from the four cycles of adipose processing) and plated in
tissue culture media.
Neonatal foreskin cultures
Neonatal human foreskins were collected, and the isola-
tion of foreskin fibroblasts was carried out using the
protocol of Ghebeh et al. 2007 [40]. In short, newborn
baby foreskins were minced and digested overnight in
Collagenase Ia (400 IU) and Hyaluronidase (100 IU) in
tissue culture media. After differential centrifugation
(90 g, 2 minutes) the fibroblasts, remaining in suspen-
sion, were collected and plated in tissue culture media.
Mesenchymal stem cell differentiation
Mesenchymal stem cell differentiation into adipocytes, os-
teocytes and chondrocytes was carried out, as per manu-
facturer’s instructions (Lonza; nb. the concentrations of all
differentiation reagents were not provided) (n=3 per
tissue, passage 3). For adipocyte differentiation, the cells
were plated at 20 000 cells/cm
2 on uncoated glass
chamber slides (Labtek II – Fisher-Scientific). Cells were
cultured in tissue culture media until 2 or 3 days post-
confluent. The media was then replaced with adipogenic
induction medium (MCGS (mesenchymal cell growth
supplement), h-insulin (recombinant), L-glutamine, dexa-
methasone, indomethacin, 3-isobutyl-1-methyl-xanthine
(IBMX) and gentamycin). After 3 days in induction media,
the cells were cultured in maintenance media (MCGS, h-
insulin (recombinant), L-glutamine and gentamycin) for a
further 3 days. An additional 2 cycles of culture in induc-
tion and maintenance media were completed. Following
this the cells were cultured in maintenance media for a
further 7 days, with media changes every 2 to 3 days.
For osteocyte differentiation cells were plated at 30
000cells/cm
2 on uncoated plastic (permanox) chamber
slides (Labtek – Fisher Scientific) and allowed to attach
for 24 hours in tissue culture media, after which it was re-
placed with osteogenic induction media (MCGS, L-
glutamine, dexamethasone, ascorbate, β-glycerophosphate
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was changed every 3–4d a y sf o r3w e e k s .
Pellet cultures (250 000 cells/pellet) were utilized for
chondrocyte differentiation. Cells were washed in serum
free media, resuspended in chondrogenic induction media
(Transforming growth factor-β3( T G F - β3), L-glutamine,
dexamethasone, ascorbate, sodium pyruvate, proline, ITS-
supplement and gentamycin), pelleted by centrifugation
(150 g, 5 minutes) and then remained untouched for 2 days.
Chondrogenic induction media was changed every 2 to
3 days for 3 weeks.
After adipocyte and osteocyte differentiation, the cells
were fixed in 4% formaldehyde (Sigma-Aldrich) for 15 mi-
nutes and then washed in PBS. Adipocyte differentiation
was assessed using Oil-Red-O (Sigma-Aldrich) to detect
lipids. Osteocytes differentiation was examined using
Alizarin Red (Sigma-Aldrich) to indicate calcium accumu-
lation. Chondrocyte differentiation was tested using
Safranin-O (Sigma-Aldrich) to identify proteoglycans in
acetone fixed sections (5 μm) of cell pellets snap frozen in
optimal cutting temperature mounting media (OCT)
(Sakura Finetek).
Flow-cytometry
Flow-cytometry was used to assess the phenotype of all tis-
sue cells (n =3 per tissue, at passage 3). Cells passaged for
flow-cytometry were washed with PBS for 15 minutes
(3x5min) then incubated in 1 mL Dispase (1 mg/mL) (Stem
Cell Technologies) and 100 μLD N a s eI( 1 0m g / m L )( R o c h e
Diagnostics), to reduce protease effects on extracellular epi-
topes, for 15 minutes at 37°C. Detached cells were collected
in PBS. The few remaining, rounded, and loosely attached
cells were detached by very gentle cell-scraping. After cen-
trifugation cells were washed in 2 mL of ice-cold FACS buf-
fer (PBS+2% FCS), centrifuged again, and resuspended in
100 μL of FACS buffer. Primary antibodies (Additional file
2) were added and incubated in the dark on ice for 30 mi-
nutes after which 2 mL of FACS buffer was added and the
cells centrifuged. The cells were then resuspended in tissue
culture media and then analyzed using a flow-cytometer.
The percentage of positive cells was calculated based on
control (unstained) cells for each cell type.
Immuno-fluorescence
Tissue cells (n =3 per tissue, at passage 3) were plated
on glass chamber slides at a density of 20 000 cells/cm
2
and cultured for 4 days then fixed in 4% formaldehyde
as previously described. Immuno-fluorescence was car-
ried out as described in Wetzig et al [41], minus bovine
serum albumin. Primary antibodies included Collagens I
and III, fibroblast surface protein (FSP) and prolyl 4-
hydroxylase, beta polypeptide (P4HB) (All from Abcam).
Secondary antibodies were AlexaFluor goat anti mouse
IgG/IgM 488 or AlexaFluor goat anti rabbit IgG 555
(Invitrogen) and DAPI (4′-6-Diamidino-2-phenylindole
1 μg/mL) (Invitrogen) was included in the secondary anti-
body solution. Each sample was stained in triplicate for
each antibody. Captured images were segmented based on
DAPI and the intensity of staining measured (Attovision
software). Cells with fluorescence intensity greater than
control wells (no primary antibody) were considered posi-
tive. The percentage of positive cells was calculated by
comparison between the number of positive cells and the
total number of cells (DAPI).
Antibody array
Tissue cells (passage 4) were passaged, pooled together
and plated at 5 000 cells/well on three 96 well plates. Cells
were cultured in tissue culture media for 3–4d a y st h e n
stained using BD lyoplate kit, as per manufacturer’si n -
structions (BD). Secondary antibody solution was modified
to; AlexaFluor 555 goat anti mouse IgG and IgM anti-
bodies (both diluted 1/400). Wells designated for rat anti-
bodies remained unstained. After staining 100 μLP B S +
DAPI (1 μg/mL)+sodium azide (0.05%) (Sigma-Aldrich)
solution was added to each well.
Wells were scanned using the BD Pathway 855 micro-
scope and Attovision software. Three by three (3x3) ad-
joining montage images were captured for both DAPI and
AlexaFluor 555 staining. Wells were examined for fluores-
cent, cellular, staining and by comparison with control
wells/cells (no primary antibody) were scored as either
negative or positive. A pair-wise comparison of antibody
expression was carried out between all tissue cells and the
percentage similarity between sample pairs calculated.
Proteomics
Total cell lysates were prepared from all tissues (n =3
per tissue, passage 4) as previously described [42]. For
two –dimensional gel electrophoresis (2DE), 50 μgo f
total protein was applied to 11 cm immobilized pH gra-
dient (IPG) strips. Isoelectric focusing was performed
using the PROTEAN IEF System (Bio-Rad) as previously
described [43]. The second dimension was carried out in
12% homogeneous Bio-Rad Criterion™ XT mini gels.
Proteins were visualized with Sypro ruby.
Stained gels were scanned at 50 μm resolution using a
Typhoon Trio Imager (General Electric). Data were ana-
lyzed using the Progenesis SameSpots software (version
7.1.0, Nonlinear Dynamics, UK) and/or PDQUEST™ ver-
sion 8.0.1 (Bio-Rad).
Differentially expressed protein spots with quantitative
changes≥1.5 were selected using ANOVA, (p<0.05).
Datasets from Progenesis and PDQUEST were subjected
to correlation coefficient analysis, as previously described
[44,45].
350 - 500 μg protein was loaded for peptide mass fin-
gerprinting (PMF). Differentially expressed protein spots
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using a Proteome Works Plus Spot Cutter (Bio-Rad,
Hercules, CA). Automated digestion was performed as
previously described [43].
Prior to liquid chromatography/mass spectrometry (LC/
MS) analysis, the extracted peptides were diluted with an
aqueous 0.1% formic acid solution. Digested peptides were
subjected to LC separation using the NanoAcquity coupled
with SynaptG2 HDMS system (Waters, Manchester UK).
All samples were analyzed in duplicate and continuum raw
data were processed by MassLynx version 4.1 and Protein
Lynx Global Server (PLGS) 2.2 (Waters, Manchester, UK)
was used for all automated data processing and database
searching. The SWISSPROT protein sequence database
and PLGS 2.2 (Waters) were used for protein identification.
A MASCOT protein score greater than 60 was considered
statistically significant (p< 0.05).
RNA isolation and qPCR
To quantitate the extent of differentiation amongst the tis-
sues and to confirm the expression of proteins identified
by antibody array and proteomics, qPCR was utilized.
RNA was extracted from osteocyte and chondrocyte
differentiation cultures and undifferentiated cells (pas-
sage 3) from all tissues (n =3 per tissue) using Qiagen
RNeasy mini kit (Qiagen) as per manufacturer’s instruc-
tions. Qiashredders were employed to lyse chondrocyte
pellets. RNA was extracted from adipocyte differenti-
ation cultures using Qiagen RNeasy lipid tissue mini kit.
Superscipt III first strand synthesis supermix for qRT-PCR
(Invitrogen) was utilized for reverse transcription. Aggre-
can (HS00153936), adiponectin (HS00605917) and osteo-
pontin (HS00959010) Taqman gene expression assays
were utilized in combination with Taqman Universal Mas-
ter Mix II No UNG (Invitrogen) to assess chondrocyte,
adipocyte and osteocyte differentiation respectively. Taq-
man gene expression assays were also used to assess the
expression of proteins identified by antibody array and
proteomics (Additional file 3). For all tissue samples (n=3
per tissue), each assay was performed in triplicate and
each experiment repeated three times. ΔΔCt values were
calculated based on Glyceraldehyde 3-phosphate dehydro-
genase (GAPDH) expression.
Statistical analysis
Data was analyzed using Graphpad-Prism software. Flow-
cytometry, immuno-fluorescence and qPCR data was ana-
lyzed using one-way ANOVA followed by Tukey’s multiple
comparison test. Probability values less than 0.05 were
considered significant. Proteomics data were analyzed
using Student’s t test, ANOVA and principal component
analysis (Progenesis SameSpots and PDQuest 2-DE ana-
lysis software).
Additional files
Additional file 1: Details of proteins identified by proteomic
analysis. Description: A table indicating the details of proteins identified
by proteomic analysis. Including comparative fold changes, molecular
weights (Da) and isoelectric point (pH).
Additional file 2: Monoclonal antibodies used for flow-cytometry
analysis. Description: A table indicating the monoclonal antibodies used
for flow-cytometry analysis. Including CD_antigen, gene name, clone
name, conjugated fluorophore and the company purchased from.
Additional file 3: Taqman gene expression assays for qPCR.
Description: A table indicating the Taqman gene expression assays used for
qPCR. Including gene name, symbol and invitrogen catalogue number.
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